These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 32330776)

  • 1. Biparametric prostate MRI and clinical indicators predict clinically significant prostate cancer in men with "gray zone" PSA levels.
    Wei CG; Chen T; Zhang YY; Pan P; Dai GC; Yu HC; Yang S; Jiang Z; Tu J; Lu ZH; Shen JK; Zhao WL
    Eur J Radiol; 2020 Jun; 127():108977. PubMed ID: 32330776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
    Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
    Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
    [No Abstract]   [Full Text] [Related]  

  • 3. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
    Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
    Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
    Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
    J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Yang J; Li J; Xiao L; Zhou M; Fang Z; Cai Y; Tang Y; Hu S
    Cancer Imaging; 2023 Sep; 23(1):81. PubMed ID: 37667341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.
    Niu XK; Li J; Das SK; Xiong Y; Yang CB; Peng T
    BMC Med Imaging; 2017 Feb; 17(1):11. PubMed ID: 28143433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment.
    Liu C; Liu SL; Wang ZX; Yu K; Feng CX; Ke Z; Wang L; Zeng XY
    Asian J Androl; 2018; 20(5):459-464. PubMed ID: 29667616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the detection rate of prostate cancer in the gray zone of PI-RADS v2 and serum tPSA by using prostate-specific antigen-age volume.
    Lu YF; Zhang Q; Chen HY; Chen JY; Pan Y; Xu CC; Xu JX; Yu RS
    Medicine (Baltimore); 2019 Jun; 98(26):e16289. PubMed ID: 31261602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.
    Druskin SC; Tosoian JJ; Young A; Collica S; Srivastava A; Ghabili K; Macura KJ; Carter HB; Partin AW; Sokoll LJ; Ross AE; Pavlovich CP
    BJU Int; 2018 Apr; 121(4):619-626. PubMed ID: 29232037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
    Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
    BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of prostate PI-RADS V2.1 score combined with serum PSA-related indicators in the detection of gray zone prostate cancer.
    Lin S; Yu X; Chen H; Chen Z; Yang Y
    Int Urol Nephrol; 2023 Nov; 55(11):2685-2693. PubMed ID: 37523077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nomogram based on PI-RADS v2.1 and clinical indicators for predicting clinically significant prostate cancer in the transition zone.
    Wei C; Pan P; Chen T; Zhang Y; Dai G; Tu J; Jiang Z; Zhao W; Shen J
    Transl Androl Urol; 2021 Jun; 10(6):2435-2446. PubMed ID: 34295730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI?
    Polanec SH; Bickel H; Wengert GJ; Arnoldner M; Clauser P; Susani M; Shariat SF; Pinker K; Helbich TH; Baltzer PAT
    Clin Radiol; 2020 Feb; 75(2):157.e1-157.e7. PubMed ID: 31690449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing prostate cancer accumulating model: combined PI-RADS v2 with prostate specific antigen and its derivative data.
    Lu YF; Zhang Q; Yao WG; Chen HY; Chen JY; Xu CC; Yu RS
    Cancer Imaging; 2019 May; 19(1):26. PubMed ID: 31122297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate imaging-reporting and data system version 2 in combination with clinical parameters for prostate cancer detection: a single center experience.
    Wang L; Luo Y; Liu T; Deng M; Huang X
    Int Urol Nephrol; 2023 Jul; 55(7):1659-1664. PubMed ID: 37171702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting prostate cancer in men with PSA levels of 4-10 ng/mL: MRI-based radiomics can help junior radiologists improve the diagnostic performance.
    Zhong JG; Shi L; Liu J; Cao F; Ma YQ; Zhang Y
    Sci Rep; 2023 Mar; 13(1):4846. PubMed ID: 36964192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer.
    Tamada T; Kido A; Takeuchi M; Yamamoto A; Miyaji Y; Kanomata N; Sone T
    Eur J Radiol; 2019 Dec; 121():108704. PubMed ID: 31669798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic Resonance Imaging-Defined Prostate-Specific Antigen Density Significantly Improves the Risk Prediction for Clinically Significant Prostate Cancer on Biopsy.
    Bhat NR; Vetter JM; Andriole GL; Shetty AS; Ippolito JE; Kim EH
    Urology; 2019 Apr; 126():152-157. PubMed ID: 30580005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
    Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the performance of PI-RADS v2 in the non-academic setting.
    Jordan EJ; Fiske C; Zagoria RJ; Westphalen AC
    Abdom Radiol (NY); 2017 Nov; 42(11):2725-2731. PubMed ID: 28451763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.